SELFDIAGNOSTICS next-generation molecular diagnostics Multitest platform is an innovative tool for launching a family of rapid molecular tests. > MULTITEST COVID-19 https://selfdiagnostics.eu/rapid-pcr-covid-multitest Selfdiagnostics Multitest COVID-19 – the rapid molecular NAAT test combines the ease of use of rapid tests and the diagnostic accuracy of laboratory PCR. ☉ PCR-LEVEL TESTING WITHOUT INVESTMENT. Very straightforward single-use test requires no investment in instruments or infrastructure. No maintenance contracts. No calibration. ☉ UNLIMITED THROUGHPUT. Each test runs independently – there is no need to wait for an instrument to finish the previous test. ☉ EASY AND PORTABLE. Just swab and test – does not require any training. The single-use test is just slightly larger than a credit card. Room temperature stable. A good fit for the following settings: ☉ HOSPITALS to increase rapid PCR testing in emergency departments and on wards immediately without investment in additional instruments. ☉ SMALL CLINICS to have modern PCR testing results without the need to set up a big lab or outsource a PCR testing service. ☉ TESTING SERVICE PROVIDERS to offer rapid PCR results for certificates or immediate diagnostics decisions. ☉ COMPANIES to keep production facilities open by discovering infected individuals reliably and rapidly. MULTITEST LONG-TERM ADVANTAGES: ☉ MASS-PRODUCIBLE. Intentionally simple and minimal component design for cost efficient mass production. Modular production line enables fast production scale-up. ☉ MULTIPLEXED. Able to differentiate up to four different organism’s RNA or DNA from one sample in a single run. Duplex panel test – Selfdiagnostics STD Multitest CT/NG is ready to be launched next after validation. ☉ EXPANDABLE. Has proven multi-sample capability. Tests from swab and urine samples are ready. Expandable to detect from blood, soil and water. IN THE PIPELINE: > MULTITEST STD https://selfdiagnostics.eu/std-multitest
| Website | https://selfdiagnostics.eu |
| Employees | 14 (10 on RocketReach) |
| Founded | 2008 |
| Phone | (372) 660-4742 |
| Industry | Biotechnology Research, Health Care, Self Diagnosis, Medical, Rapid Medical Tests, Pharmaceutical |
| Keywords | Molecular Diagnostics, Pcr Testing, Covid Testing, Molecular Diagnostic Tests, Point Of Care Diagnostics, Infectious Disease Testing, Next Generation Diagnostics, Rapid Diagnostics, Diagnostic Platform, In Vitro Diagnostics, Medical Diagnostics, Clinical Diagnostics, Diagnostic Tools, Healthcare Diagnostics, Disease Detection, Health Technology, Medical Technology, Biotechnology |
| Competitors | bioMérieux, Roche, Thermo Fisher Scientific, BD, Cepheid, Siemens Healthineers, Abbott, Hologic, Inc., OraSure Technologies, Genomic Health +43 more (view full list) |
Looking for a particular Selfdiagnostics Deutschland GmbH employee's phone or email?
Harri Peiker is the CEO of Selfdiagnostics Deutschland GmbH.
10 people are employed at Selfdiagnostics Deutschland GmbH.